Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Rexahn Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Termination
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
Details : The company had previously disclosed that it was evaluating the development strategy for RX-5902, including whether to proceed with the trial.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
September 04, 2020
Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Rexahn Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 06, 2013
Lead Product(s) : RX-5902
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable